Production of Iodine-124 and Its Application in PET Molecular Imaging

doi:10.7538/tws.2018.31.03.0188

Abstract

Abstract:

Iodine-124 (¹²⁴I) is an isotope for positron as well as unique chemical properties and convenient halflife of 4.2 days. Its modes of decay are 74.4% electron captureand 25.6% positron emission. Until recently, ¹²⁴I is not considered to be an attractive isotope for medical application owing to its complex radioactive decay scheme and the high-energy gamma rays. ¹²⁴I can be made by numerous nuclear reactions via a cyclotron. The most common starting material is ¹²⁴Te and ¹²⁴I that can decay to ¹²⁴Te. ¹²⁴I as sodium iodine form can be used to image the thyroid and corresponding tumor using positron emission tomography (PET) directly. The ¹²⁴I nuclide can be chemically bonded to a pharmaceutical to form a positron-emitting radiopharmaceutical. Radioiodination of ¹²⁴I can be efficiency attached to small molecular, peptide or antibody within radiochemistry labs. Nowadays, due to the increasing application of PET in medical oncology, pharmacokinetics and drug metabolism, ¹²⁴I-labeled radiopharmaceuticals are now becoming one of the most useful tools for PET imaging. ¹²⁴I-labeled monoclonal antibodies (mAbs) are being used for clinical immuno-PET. Among them, ¹²⁴I-cG250 accurately identifies clear-cell renal carcinoma attracting clinical attentions. Based on those progress, this review outlined the physical property, production and application of ¹²⁴I in PET molecular imaging.

Key words: iodine-124, positron emission-computed tomography, tumor, molecular imaging, solid target nuclide production

摘要：

¹²⁴I是一种半衰期较长的正电子核素（T_1/2=4.2 d），由于其生产工艺要求较高、复杂的衰变纲图以及辐射出的超高能量γ射线，在过去很长一段时间里限制了其临床应用。如今，随着回旋加速器生产核素技术的进步及正电子发射型计算机断层显像（PET）技术在肿瘤及药物药代动力学等研究中应用不断拓展，使得¹²⁴I核素标记的化合物成为具有应用价值的核医学PET分子探针。本文主要对¹²⁴I正电子核素的核性质、生产方式、常规标记方法以及在PET分子影像方面的临床应用进行阐述。

关键词: 碘-124, 正电子发射型计算机断层显像, 肿瘤, 分子影像, 固体靶核素生产

LI Liqiang;WANG Feng;LIU Teli;ZHU Hua;YANG Zhi. Production of Iodine-124 and Its Application in PET Molecular Imaging[J]. Journal of Isotopes, 2018, 31(3): 188-197.

李立强;王风;刘特立;朱华;杨志. 碘-124的生产、标记及在肿瘤PET分子影像的应用[J]. 同位素, 2018, 31(3): 188-197.

References

［1］Koehler L, Gagnon K, McQuarrie S, et al. Iodine-124: a promising positron emitter for organic PET chemistry［J］. Molecules, 2010, 15(4): 2686-2718.
［2］Chacko A M, Divgi C R. Radiopharmaceutical chemistry with iodine-124: a non-standard radiohalogen for positron emission tomography［J］. Med Chem, 2011, 7(5): 395-412.
［3］Pentlow K S, Graham M C, Lambrecht R M, et al. Quantitative imaging of iodine-124 with PET［J］. J Nucl Med, 1996, 37(9): 1557-1562.
［4］Kondo K, Lambrecht R M, Norton E F, et al. Cyclotron isotopes and radiopharmaceuticals ⅩⅫ. Improved targetry and radiochemistry for production of ¹²³I and ¹²⁴I［J］. Int J Appl Radiat Isot, 1977, 28(9): 765-771.
［5］Lambrecht R M, Sajjad M, Qureshi M A, et al. Production of iodine-124［J］. Journal of Radioanalytical & Nuclear Chemistry, 1988, 127(2): 143-150.
［6］Scholten B, Kovács Z, Tárkányi F, et al. Excitation functions of ¹²⁴Te(p, xn) ^124,123I reactions from 6 to 31 MeV with special reference to the production of ¹²⁴I at a small cyclotron［J］. Applied Radiation & Isotopes, 1995, 46(4): 255-259.
［7］Schmitz J. The production of ［¹²⁴I］ iodine and ［⁸⁶Y］yttrium［J］. European Journal of Nuclear Medicine & Molecular Imaging, 2011, 38(1): 4-9.
［8］Nagatsu K, Fukada M, Minegishi K, et al. Fully automated production of iodine-124 using a vertical beam［J］. Applied Radiation & Isotopes Including Data Instrumentation & Methods for Use in Agriculture Industry & Medicine, 2011, 69(1): 146-157.
［9］Qaim S M, Hohn A, Bastian T, et al. Some optimisation studies relevant to the production of high-purity at a small-sized cyclotron［J］. Applied Radiation & Isotopes, 2003, 58(1): 69-78.
［10］Bastian T, Coenen H H , Qaim S M. Excitation functions of ¹²⁴Te(d, xn) ^124,125I reactions from threshold up to 14 MeV: comparative evaluation of nuclear routes for the production of ¹²⁴I［J］. Applied Radiation & Isotopes Including Data Instrumentation & Methods for Use in Agriculture Industry & Medicine, 2001, 55(3): 303-308.
［11］Hassan K F, Qaim S M, Saleh Z A, et al. ³He-particle-induced reactions on Sb for production of ¹²⁴I［J］. Applied Radiation & Isotopes Including Data Instrumentation & Methods for Use in Agriculture Industry & Medicine, 2006, 64(4): 409.
［12］Van den Bosch R, De Goeij J J, Van der Heide J A, et al. A new approach to target chemistry for the iodine-123 production via the ¹²⁴Te(p, 2n) reaction［J］. Int J Appl Radiat Isot, 1977, 28(3): 255-261.
［13］Glaser M, Mackay D B, Ranicar A S O, et al. Improved targetry and production of iodine-124 for PET studies［J］. Radiochimica Acta/international Journal for Chemical Aspects of Nuclear Science & Technology, 2004, 92(12): 951-956.
［14］Zaidi J H, Qaim S M, Stöcklin G. Excitation functions of deuteron induced nuclear reactions on natural tellurium and enriched 122 Te: Production of ¹²³I via the ¹²²Te(d,n) ¹²³I-process［J］. International Journal of Applied Radiation & Isotopes, 1983, 34(10): 1425-1430.
［15］Oberdorfer F, Helus F, Maierborst W. Experiences in the routine production ofI via the Te(p, 2n)I reaction with a low energy cyclotron［J］. Journal of Radioanalytical Chemistry, 1981, 65(1-2): 51-56.
［16］Apelt H, Blessing G, Knieper J, et al. Some technical improvements in the production of ¹²³I via the ¹²⁴Te(p, 2n) ¹²³I reaction at a compact cyclotron［J］. International Journal of Applied Radiation & Isotopes, 1981, 32(8): 581-587.
［17］Sheh Y, Koziorowski J, Balatoni J, et al. Low energy cyclotron production and chemical separation of “no carrier added” iodine-124 from a reusable, enriched tellurium-124 dioxide/aluminum oxide solid solution target［J］. Radiochimica Acta, 2000, 88(3-4): 169.
［18］Sajjad M, Bars E, Nabi H A. Optimization of ¹²⁴I production via ¹²⁴Te(p,n)¹²⁴I reaction［J］. Applied Radiation & Isotopes, 2006, 64(9): 965-970.
［19］Nye J A, Avilarodriguez M A, Nickles R J. Production of ［¹²⁴I］ iodine on an 11 MeV cyclotron［J］. Radiochimica Acta, 2006, 94(4): 213-216.
［20］Alekseev I E, Darmograi V V，Marchenkov N S. Development of diffusion-thermal methods for preparing ⁶⁷Cu and ¹²⁴I for radionuclide therapy and positron emission tomography［J］. Radiochemistry, 2005, 47(5): 502-509.
［21］Smith G E, Sladen H L, Biagini S C, et al. Inorganic approaches for radiolabelling biomolecules with fluorine-18 for imaging with positron emission tomography［J］. Dalton Trans, 2011, 40(23): 6196.
［22］Knust E J, Dutschka K, Weinreich R. Preparation of ¹²⁴I solutions after thermodistillation of irradiated ¹²⁴TeO₂targets［J］. Applied Radiation & Isotopes, 2000, 52(2): 181-184.
［23］Blasberg R, Roelcke U, Weinreich R. ［¹²⁴I］ iododeoxyuridine imaging tumor proliferation［J］. Journal of Nuclear Medicine, 1996, 37(Suppl 5): 106-128.
［24］Van d B R, De Goeij J J, Ja V D H，et al. A new approach to target chemistry for the iodine-123 production via the ¹²⁴Te(p, 2n) reaction［J］. International Journal of Applied Radiation & Isotopes，1977, 28(3): 255.
［25］Shikata E, Amano H. Dry-distillation of iodine-131 from several tellurium compounds［J］. Journal of Nuclear Science & Technology, 1973, 10(10): 80-88.
［26］Braghirolli A M S, Waissmann W, Silva J B D, et al. Production of iodine-124 and its applications in nuclear medicine［J］. Applied Radiation & Isotopes, 2014, 90(90C): 138-148.
［27］Zweit J, Sharma H L, Goodall R, et al. Excitation functions of proton induced reactions in natural tellurium: production of no carrier added I-124 for PET applications［J］. Proceed-ings of the Fourth International Workshop on Targetry and Target Chemistry, 1991, 63(5): 76-78.
［28］Robinson M K, Doss M, Shaller C, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2-diabody［J］. Cancer Research, 2005, 65(4): 1471-1478.
［29］Dekker B, Keen H, Shaw D, et al. Functional comparison of annexin V analogues labeled indirectly and directly with iodine-124［J］. Nuclear Medicine & Biology, 2005, 32(4): 403.
［30］Verel I, Visser G W M, Vosjan M J W D, et al. High-quality ¹²⁴I-labelled monoclonal antibodies for use as PET scouting agents prior to ¹³¹I-radioimmunotherapy［J］. European Journal of Nuclear Medicine & Molecular Imaging, 2004, 31(12): 1645-1652.
［31］Verel I, Visser G W, Boerman O C, et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET［J］. Cancer Biotherapy & Radiopharmaceuticals, 2003, 18(4): 655.
［32］Sundaresan G, Yazaki P J, Shively J E, et al. ¹²⁴I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice［J］. Journal of Nuclear Medicine Official Publication Society of Nuclear Medicine, 2003, 44(12): 1962-1969.
［33］Glaser M, Brown D J, Law M P, et al. Preparation of no-carrier-added ［¹²⁴I］ A14-iodoinsulin as a radiotracer for positron emission tomography［J］. Journal of Labelled Compounds & Radiopharmaceuticals, 2001, 44(6): 465-480.
［34］Daghighian F, Pentlow K S, Larson S M, et al. Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124 labelled 3F8 monoclonal antibody in glioma［J］. European Journal of Nuclear Medicine, 1993, 20(5): 402-409.
［35］Westera G, Reist H W, Buchegger F, et al. Radioimmuno positron emission tomography with monoclonal antibodies: a new approach to quantifying in vivo tumour concentration and biodistribution for radioimmunotherapy［J］. Nuclear Medicine Communications, 1991, 12(5): 429.
［36］Bakir M A, Eccles S, Babich J W, et al. C-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies［J］. Journal of Nuclear Medicine Official Publication Society of Nuclear Medicine, 1992, 33(12): 2154-2160.
［37］Glaser M, Carroll V A, Collingridge D R, et al. Preparation of the iodine-124 derivative of the Bolton–Hunter reagent (［¹²⁴I］I-SHPP) and its use for labelling a VEGF antibody as a PET tracer［J］. Journal of Labelled Compounds & Radiopharmaceuticals, 2002, 45(12): 1077-1090.
［38］Divgi C R, Pandit-Taskar N, Jungbluth A A, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (I-cG250) and PET in patients with renal masses: a phase I trial［J］. Lancet Oncology, 2007, 8(4): 304-310.
［39］Brouwers A H, Dorr U, Lang O, et al. ¹³¹I-cG250 monoclonal antibody immunoscintigraphy versus ［¹⁸F］-FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study［J］. Nucl Med Commun, 2002, 23(3): 229-236.
［40］Pryma D A, O'Donoghue J A, Humm J L, et al. Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody ¹²⁴I-cG250［J］. J Nucl Med, 2011, 52(4): 535-540.
［41］Salacinski P, Hope J, Mclean C. Iodination of proteins glycoproteins and peptides using a solid phase oxidizing agent (IODO-GEN)［J］. Analytical Biochemistry, 1981: 117-146.
［42］Lee F T, Hall C, Rigopoulos A, et al. Immuno-PET of human colon xenograft bearing BALB/c nude mice using ¹²⁴I-CDR-grafted humanized A33 monoclonal antibody［J］. Journal of Nuclear Medicine Official Publication Society of Nuclear Medicine, 2001, 42(5): 764.
［43］Sundaresan G, Yazaki P J, Shively J E, et al. ¹²⁴I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice［J］. Journal of Nuclear Medicine Official Publication Society of Nuclear Medicine, 2003, 44(12): 1962-1969.
［44］Guenther I, Wyer L, Knust E J, et al. Radiosynthesis and quality assurance of 5-［¹²⁴I］Iodo-2′-deoxyuridine for functional PET imaging of cell proliferation［J］. Nuclear Medicine & Biology, 1998, 25(4): 359-365.
［45］Blasberg R, Roelcke U R, Beattie B, et al. Imaging brain tumor proliferative activity with ［¹²⁴I］ iododeoxyuridine［J］. Cancer Research, 2000, 60(3): 624-635.
［46］Roelcke U, Hausmann O, Merlo A, et al. PET imaging drug distribution after intratumoral injection: the case for (124)I-iododeoxyuridine in malignant gliomas［J］. Journal of Nuclear Medicine Official Publication Society of Nuclear Medicine, 2002, 43(11): 1444-1451.
［47］Tjuvajev J G, Doubrovin M, Akhurst T, et al. Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression［J］. J Nucl Med, 2002, 43(8): 1072-1083.
［48］Dekker B, Keen H, Lyons S, et al. MBP-annexin V radiolabeled directly with iodine-124 can be used to image apoptosis in vivo using PET［J］. Nuclear Medicine & Biology, 2005, 32(3): 241.
［49］Reischl G, Dorow D S, Cullinane C, et al. Imaging of tumor hypoxia with ［I-124］ IAZA in comparison with ［F-18］ FMISO and ［F-18］FAZA first small animal PET results［J］. Journal of Pharmacy & Pharmaceutical Sciences, 2007, 10(2): 203-211.
［50］Bading J R, Shields A F. Imaging of cell proliferation: status and prospects［J］. Journal of Nuclear Medicine Official Publication Society of Nuclear Medicine, 2008, 49 (Suppl 2): 64S.
［51］Blasberg R G, Roelcke U, Weinreich R, et al. Imaging brain tumor proliferative activity with ［¹²⁴I］ iododeoxyuridine［J］. Cancer Res, 2000, 60(3): 624-635.
［52］Fadok V A, Voelker D R, Campbell P, et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages［J］. J Immunol, 1992, 148(7): 2207-2216.
［53］Verel I, Visser G W, Boerman O C, et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET［J］. Cancer Biother Radiopharm, 2003, 18(4): 655-661.
［54］van Dongen G A, Visser G W, Lub-de Hooge M N, et al. Immuno-PET: a navigator in monoclonal antibody development and applications［J］. Oncologist, 2007, 12(12): 1379.
［55］Verel I V, Visser G W, Dongen G A. The promise of immuno-PET in radioimmunotherapy［J］. Journal of Nuclear Medicine, 2005, 46(Suppl 1): 164S-171S.
［56］Nayak T K, Brechbiel M W. Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges［J］. Bioconjug Chem, 2009, 20(5): 825.
［57］Wilbur D S, Hadley S W, Hylarides M D, et al. Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer［J］. Journal of Nuclear Medicine, 1989, 30(2): 216-226.
［58］Zechmann C M, Afsharoromieh A, Armor T, et al. Radiation dosimetry and first therapy results with a ¹²⁴I/¹³¹I labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy［J］. European Journal of Nuclear Medicine & Molecular Imaging, 2014, 41(7): 1280-1292.
［59］Knowles S M, Tavare R, Zettlitz K A, et al. Applications of immunoPET: using ¹²⁴I anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer［J］. Clin Cancer Res, 2014, 20(24): 6367-6378.
［60］O’Donoghue J A, Smith-Jones P M, Humm J L, et al. ¹²⁴I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET［J］. J Nucl Med, 2011, 52(12): 1878-1885.
［61］Lee C L, Wahnishe H, Sayre G A, et al. Radiation dose estimation using preclinical imaging with ¹²⁴I-metaiodobenzylguanidine (MIBG) PET［J］. Medical Physics, 2010, 37(9): 4861-4867.
［62］Ruhlmann M, Jentzen W, Ruhlmann V, et al. High level of agreement between pretherapeutic ¹²⁴I PET and intratherapeutic ¹³¹I imaging in detecting iodine-positive thyroid cancer metastases［J］. J Nucl Med, 2016, 57(9): 1339-1342.

[1]	ZHAO Hailong;LI Hongyu. Research Progress of ⁶⁴Cu-Radiopharmaceuticals in Clinical Trial for Tumor Diagnosis [J]. Journal of Isotopes, 2021, 34(1): 78-88.
[2]	HUANG Xuhu;LI Hongyu. Development of Radiolabeled Duramycin for Apoptosis Imaging [J]. Journal of Isotopes, 2020, 33(6): 435-442.
[3]	WANG Miao;TONG Yongpeng. The Progress and Prospect of Boron Neutron Capture Therapy [J]. Journal of Isotopes, 2020, 33(1): 14-26.
[4]	MA Jingxin;WU Zhou;JIANG Shende;WANG Hongliang;WU Zhifang. Synthesis and Biological Evaluation of 3-O-(2-¹⁸F-fluoroethyl)-L-DOPA as A Potential PET Agent for Tumor Imaging [J]. Journal of Isotopes, 2018, 31(5): 310-317.
[5]	XU Zhongjie;TU Yahui;ZHONG Jiaqi;SUN Wen;WANG Zhonghua;WANG Haoran;BAI Shaofei;WU Fanhong. Syntheses of Stable Isotopelabeled 1-(3-Methoxy-Phenyl)-［4-(4-Fluoro-2-Methoxy-D₃-Phenylaminemethyl］-1h-［1,2,3］Triazole [J]. Journal of Isotopes, 2018, 31(4): 241-247.
[6]	LU Guo-xiu;ZHANG Guo-xu;HAO Shan-hu;GUO Jia;ZHANG Wen-wen;WANG Zhi-guo;ZHANG Jing-hua. The Value of PET/CT Imaging in Alzheimer’s Disease Patients with Different Levels of Estradiol [J]. Journal of Isotopes, 2017, 30(4): 276-282.
[7]	CHEN Mei-jie;CHEN Song;YIN Ya-fu;LI Ya-ming. The Application of PET/CT in Predicting and Evaluating the Therapeutic Response in Chemotherapy of Solid Tumor [J]. Journal of Isotopes, 2017, 30(2): 148-152.
[8]	LI Xue-na;YIN Ya-fu;DU Bu-lin;LI Ya-ming. Effect of NOX 4 on the Invasion and Metastasis of Breast Cancer Cells with High Glucose Metabolism [J]. Journal of Isotopes, 2016, 29(2): 76-81.
[9]	WANG Rong-fu. Application Study on Isotope Tracing RRL Tumor Angiogenesis Imaging [J]. Journal of Isotopes, 2015, 28(4): 201-206.
[10]	NIE Da-hong;TANG Gang-hua. Research Progress of Amino Acid Metabolism PET Imaging in Tumor [J]. Journal of Isotopes, 2015, 28(4): 214-224.
[11]	GAO Xia;ZHANG Bin;WANG Bin;HUANG Hong-bo;LI Xin-ping. Biodistribution and Micro-PET Imaging of ¹⁸F-FDG、¹⁸F-RGD and ¹⁸F-FET in LN229 Glioma Model [J]. Journal of Isotopes, 2015, 28(3): 155-159.
[12]	JIA Li-na;ZHANG Lan. Application of ¹⁸F-Labeling Positron Molecular Probes in Tumor Receptor Imaging [J]. Journal of Isotopes, 2015, 28(2): 121-128.
[13]	HU Hong;TANG Gang-hua;HU Kong-zhen. Progress in Molecular Imaging of Acidic Tumor pH [J]. Journal of Isotopes, 2014, 27(3): 179-187.
[14]	LU Xia;ZHANG Hua-bei. Diversity of Radioprobes Targeted to Tumor Angiogenesis on Molecular Functional Imaging [J]. Journal of Isotopes, 2013, 26(4): 198-203.
[15]	MA Wen-hui;WANG Jing;YANG Wei-dong;LI Gui-yu;MA Xiao-wei;WANG Zhe. Biodistribution and SPECT Imaging of ⁹⁹Tc^m Labeling NGR Peptide in Nude Mice Bearing Human HePG2 Hepatoma [J]. Journal of Isotopes, 2012, 25(1): 27-32.